Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.

Trial Details

NCT ID
NCT07054346
Phase
PHASE1
Sponsor
Thomas Hope
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 177 Lutetium Prostate-Specific Membrane Antigen 617
  • Actinium-225 Prostate-Specific Membrane Antigen 617
  • Non-investigational, Prostatectomy
  • Prostate Tissue Collection
  • Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
  • Blood Sample Collection
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Age ≥18 years.
  • Histologically confirmed prostate adenocarcinoma.
  • High-risk disease as defined as meeting 1 or more of the 3 following criteria:
  • Gleason score of 4+4 disease or higher, Or Gleason 4+3 with large cribriform component (defined as \>0.25 mm in short diameter)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →